Optimal therapy of pubertal disorders in precocious/early puberty

Journal of Pediatric Endocrinology and Metabolism

Volumn 14, Issue SUPPL. 2, 2001, Pages 985-995

  Tato L ^a   Savage, M O ^a   Antoniazzi, F ^a   Buzi, F ^a   Di Maio, S ^a   Oostdijk, W ^a   Pasquino, A M ^a   Raiola, G ^a   Saenger, P ^a   Tonini, G ^a   Voorhoeve, P G ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Consensus guidelines; Early puberty; Precocious puberty; Pubertal disorders; Puberty; Therapy for pubertal disorders

Indexed keywords

CANCER GROWTH FACTOR; FOLLITROPIN; GONADORELIN; GONADORELIN AGONIST; GROWTH HORMONE; LUTEINIZING HORMONE;

AGE; ARTICLE; BODY COMPOSITION; BODY HEIGHT; BONE MASS; BREAST DEVELOPMENT; CHILD; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG WITHDRAWAL; ECHOGRAPHY; ENDOCRINE SYSTEM EXAMINATION; FEMALE; FOLLOW UP; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; IDIOPATHIC DISEASE; INCIDENCE; MALE; MEDICAL DECISION MAKING; MENSTRUAL CYCLE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PRECOCIOUS PUBERTY; PUBERTY DISORDERS; REVIEW; TREATMENT OUTCOME;

EID: 0034885235     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/jpem-2001-s211     Document Type: Article

References (76)

1. Clinical review: Pathophysiology and treatment of sexual precocity
2. Variations in the pattern of pubertal changes in girls
3. Secondary sexual characteristics and menses in young girls seen in office practice: A study from the pediatric research in office settings network
4. Puberty: Ontogeny, neuroendocrinology, physiology, and disorder
5. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: Implications for evaluation and treatment
6. Etiology of central precocious puberty in males: The results of the Italian Study Group for Physiopathology of Puberty
7. Etiology and age incidence of precocious puberty in girls: A multicentric study
8. The duration of puberty in girls is related to the timing of its onset
9. Pelvic ultrasonography: Early differentiation between isolated premature thelarche and central precocious puberty
10. Gonadotropin secretory dynamics during puberty in normal girls and boys
11. Laboratory monitoring of children with precocious puberty
12. Diagnosis of central precocious puberty: Endocrine assessment
13. Normal ranges for immunochemiluminometric gonadotropin assays
14. Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty
15. Diagnostic value of fluorometric assays in the evaluation of precocious puberty
16. A single-sample, subcutaneous gonadotropin-releasing hormone test for central precocious puberty
17. A single sample subcutaneous luteinizing hormone (LH)-releasing hormone (LHRH) stimulation test for monitoring LH suppression in children with central precocious puberty receiving LHRH agonists
18. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: Evaluation by sensitive gonadotropin assays and the leuprolide stimulation test
19. Estrogen levels in childhood determined by an ultra-sensitive recombinant cell bioassay
20. Use of an ultrasensitive recombinant cell bioassay to determine estrogen levels in girls with precocious puberty treated with a luteinizing hormone-releasing hormone agonist
21. Thelarche variant: A new syndrome of precocious sexual maturation?
22. Presentation and the gonadotropin response to luteinizing hormone-releasing hormone
23. Natural history of premature thelarche in Olmsted County, Minnesota, 1940 to 1984
24. Progression of premature thelarche to central precocious puberty
25. Isolated premature thelarche and thelarche variant: Clinical and auxological follow-up of 119 girls
26. Premature thelarche: A long-term follow-up
27. Prognostic signs in the evolution of premature thelarche by discriminant analysis
28. Outcome of premature thelarche: Relation to puberty and final height
29. Estrogen levels in girls with premature thelarche compared with normal prepubertal girls as determined by an ultrasensitive recombinant cell bioassay
30. Ovarian microcysts in girls with isolated premature thelarche
31. Ovaries in sexual precocity
32. Normal and almost normal precocious variations in pubertal development - Premature pubarche and premature thelarche revisited
33. Targeting transforming growth factor alpha expression to discrete loci of the neuroendocrine brain induces female sexual precocity
34. Transforming growth factor alpha contributes to the mechanism by which hypothalamic injury induces precocious puberty
35. Some hypothalamic hamartomas contain transforming growth factor alpha, a puberty-inducing growth factor, but not luteinizing hormone-releasing hormone neurons
36. The luteinizing hormone-releasing hormone-secreting hypothalamic hamartoma is a congenital malformation
37. Hypothalamic-pituitary function and growth in children with intracranial lesions
38. Precocious sexual development: A clinical study of 100 children
39. Precocious puberty. A report of 96 cases
40. Tables for predicting adult height from skeletal age
41. Selection of children with precocious puberty for treatment with gonadotropin releasing hormone analogs
42. Precocious puberty in girls: Early diagnosis of a slowly progressing variant
43. Preserving adult height potential in girls with idiopathic true precocious puberty
44. Unsustained or slowly progressive puberty in young girls: Initial presentation and long-term follow-up of 20 untreated patients
45. Behaviour problems and social competence in girls with true precocious puberty
46. Growth analysis up to final height and psychosocial adjustment of treated and untreated patients with precocious puberty
47. Long term treatment of male and female precocious puberty by periodic administration of a long acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules
48. Pubertal development, growth and final height in girls with sexual precocity after therapy with the GnRH analogue D-Trp-6-LH-RH. A report on 15 girls, followed after cessation of gonadotrophin suppressive therapy
49. Final heights in girls with central precocious puberty following GnRH agonist induced pituitary-gonadal suppression
50. Effects of luteinizing hormone-releasing hormone agonists on final height in luteinizing hormone-releasing hormone-dependent precocious puberty
51. Taille définitive des pubertés précoces
52. Final height in girls with central precocious puberty. Comparison of two different luteinizing hormone-releasing hormone agonist treatments
53. Final height after long-term treatment with triptorelin slow release for central precocious puberty: Importance of statural growth after interruption of treatment
54. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty
55. Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years
56. Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty: The Dutch experience
57. Randomised trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years
58. Lack of effect of GnRH agonists on final height in girls with advanced puberty: A randomized long-term pilot study
59. Use of combined Gn-RH agonist and hGH therapy for better attaining the goals in precocious puberty treatment
60. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone
61. Gonadotropin-releasing hormone agonist treatment of girls with constitutional short stature and normal pubertal development
62. The effects of the estrogen receptor blocker, Faslodex (ICI 182,780), on estrogen-accelerated bone maturation in mice
63. Ovulation and menstrual function of adolescent girls with central precocious puberty after therapy with gonadotropin-releasing hormone agonists
64. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: Long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty
65. Early polycystic ovary-like syndrome in girls with central precocious puberty and exaggerated adrenal response
66. How common are polycystic ovaries in normal women and what is their significance for the fertility of the population?
67. Reduction of bone density: An effect of gonadotropin releasing hormone analogue treatment in central precocious puberty
68. Bone mineral metabolism in girls with precocious puberty during gonadotropin releasing hormone agonist treatment
69. Bone mineral content in girls with precocious puberty treated with gonadotropin-releasing hormone analog
70. Bone mineral density during treatment of central precocious puberty
71. Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment
72. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females
73. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: Final height, body proportions, body composition, bone mineral density, and reproductive function
74. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty
75. Experience with cyproterone acetate in the treatment of precocious puberty